Comparative Analysis of Consolidative and Salvage Stereotactic Ablative Radiotherapy for Primary Lung Tumors in Stage IV Non-Small Cell Lung Cancer

Overview

This study compares the efficacy and safety of consolidative versus salvage stereotactic ablative radiotherapy (SABR) for primary lung tumors in stage IV non-small cell lung cancer (NSCLC). Results indicate comparable local progression-free survival, distant metastasis-free survival, and overall survival between the two approaches, with no significant differences in safety profiles.

Background

Lung cancer is the leading cause of cancer-related mortality globally, with NSCLC accounting for approximately 85% of cases. Many patients present with stage IV disease, where systemic therapies have improved survival outcomes. However, the optimal timing for SABR to the primary tumor remains unclear.

Data Highlights

Key Findings

• Consolidative and salvage SABR showed comparable local progression-free survival (LPFS), distant metastasis-free survival (DMFS), and overall survival (OS).
• EGFR/ALK mutation status was associated with improved LPFS, DMFS, and OS.
• Oligometastasis predicted superior overall survival.
• Grade ≥2 radiation pneumonitis occurred in 12.2% of patients, with no significant difference between groups.

Clinical Implications

The findings indicate that the choice between consolidative and salvage SABR may depend on individual patient factors, such as tumor anatomy and anticipated toxicity.

Conclusion

Consolidative and salvage SABR for primary lung tumors in stage IV NSCLC yield similar oncologic outcomes.

Related Resources & Content

1. Gensheimer et al., JAMA Oncology, 2023 -- Individualized SABR for Lung Tumors
2. Joe Y. Chang, MD, PhD, FASTRO, FACR, The ASCO Post, 2025 -- Long-Term Survival With Stereotactic Ablative Radiotherapy vs Surgery for Early-Stage NSCLC
3. Heinzerling et al., The ASCO Post, 2024 -- Primary Lung Tumor SBRT Followed by Concurrent Mediastinal Chemoradiotherapy and Immunotherapy Consolidation in Locally Advanced NSCLC
4. Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline, PubMed, 2023
5. The ASCO Post — Primary Lung Tumor SBRT Followed by Mediastinal Chemoradiotherapy in Locally Advanced NSCLC
6. Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline - PubMed
7. Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial | Oncology | JAMA Oncology | JAMA Network